The Comparison of Interleukin-17 and Interleukin-10 with Systemic Lupus Erythematosus Disease Activity

Dwitya Elvira; Iris Rengganis; Rudy Hidayat; Hamzah Shatri

doi:10.3889/oamjms.2020.4782

Authors

Dwitya Elvira Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Iris Rengganis Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Rudy Hidayat Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Hamzah Shatri Division of Psychosomatic and Palliative Medicine, Department of Internal Medicine, Faculty of Medicine University of Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.4782

Keywords:

Interleukin-17, Interleukin-10, Systemic Lupus Erythematosus, disease activity

Abstract

AIM: This study was conducted to compare means of interleukin-17 (IL-17) (Th17 cytokines) and interleukin-10 (IL-10) (T-regulatory cytokines) as pro-inflammatory and anti-inflammatory cytokine with disease activity of systemic lupus erythematosus (SLE) and to investigate correlation between IL-17 cytokine serums with IL-10 in SLE patients.

METHODS: This study recruited total of 68 SLE patients which included 34 active and 34 inactive patients based on MEX-SLEDAI as disease activity tool measurement and subjects were selected using consecutive sampling method. Blood samples were taken from subjects and IL-17 and IL-10 were measured using ELISA method. Data were analyzed with SPSS 26 software.

RESULTS: Mean IL-17 was 19.67 ± 1.299 pg/ml in active SLE group and 19.78 ± 1.187 pg/ml in inactive group. Median of IL-10 in active group was 3.63 pg/ml and in inactive group was 2.52 pg/ml, respectively. No significant mean differences were found of IL-17 and IL-10 between active and inactive SLE patients (p > 0.005). We found significant positive correlation between IL-17 and IL-10 (p < 0.005; r = 0.529).

CONCLUSION: There were no significant mean differences of IL-17 and IL-10 between active and inactive SLE patients. However, we found elevated result of IL-10 in active SLE than inactive. There was positive correlation between IL-17 and IL-10.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Carter E, Barr S, Clarke A. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. https://doi.org/10.1038/ nrrheum.2016.137 PMid:27558659

Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2018;30(2):144-50. PMid:29251660

Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology. 2017;56(11):1945-61. https://doi.org/10.1093/ rheumatology/kex260 PMid:28968809

Chavele K, Ehrenstein M. Regulatory T-cells in SLE and rheumatoid arthritis. FEBS. 2011;585(23):3603-10. https://doi. org/10.1016/j.febslet.2011.07.043 PMid:21827750

Sonawale A, Bohara V, Bichile L. Evaluation of the association between CD4, CD8, CD25 cell counts and SLE in active disease and in remisson. J Assoc Physician India. 2017;65(4):37-42. PMid:28527162

Elvira D. The role of T-regulatory expression in autoimmune thyroid disease and its association with thyroid antibody. J Autoimmune Disord. 2016;2(2):19. https://doi.org/10.21767/2471-8513.100019

Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J. Autoimmun. 2018;87:1-15. https://doi.org/10.1016/j.jaut.2017.12.007 PMid:29275836

Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders. Molecules. 2017;22(1):134. https://doi. org/10.3390/molecules22010134 PMid:28098832

Rother N, Van der Vlag J. Disturbed T cell signaling and altered Th17 and regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus. Front Immunol. 2015;6:610. https://doi.org/10.3389/fimmu.2015.00610 PMid:26648939

Guo B. IL-10 modulates Th17 pathogenicity during autoimmune diseases. J Clin Cell Immunol. 2016;7(2):400. https://doi. org/10.4172/2155-9899.1000400 PMid:27308096

Weckerie CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011;40(1):42-9. https://doi.org/10.1007/s12016-009-8192-4 PMid:20063186

Gergianaki I, Bertsias G. Systemic lupus erythematosus in primary care: An update and practical messages for the general practitioner. Front Med. 2018;5:161. https://doi.org/10.3389/ fmed.2018.00161 PMid:29896474

Zhang R, Li Y, Pan B, Li Y, Liu A, Li X. Increased expression of hub gene CXCL-10 in peripheral blood mononuclear cells of patients in systemic lupus erythematosus. Exp Ther Med. 2019;18(5):4067-75. https://doi.org/10.3892/etm.2019.8013 PMid:31616519

Kakati S, Teronpi R, Barman B. Frequency, pattern and determinants of flare in systemic lupus erythematosus. Egyp Rheumatol. 2015;37(4):S55-9. https://doi.org/10.1016/j. ejr.2015.08.002

Reategui-Sokolova C, Rodriguez-Bellido Z, Gamboa- Cardenas RV, Medina M, Zevallos F, Pimentel-Quiroz VR, et al. Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients. Lupus. 2019;28(11):1344-9. https://doi.org/10.1177/0961203319876998 PMid:31551028

Freire EA, Souto LM, Ciconelli RM. Assessment measures in systemic lupus erythematosus. Rev Bras Reumatol. 2011;51(1):70-80. PMid:21412607

Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Treg/Th17 cytokine imbalance in lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine. 2015;72(2):146-53. https://doi.org/10.1016/j.cyto.2014.12.027 PMid:25647269

Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76(2):280-7. https://doi.org/10.1016/j.cyto.2015.05.007 PMid:26073684

Yao Y, Wang JB, Xin MM, Li H, Liu B, Wang LL, et al. Balance between inflammatory and regulatory cytokines in systemic lupus erythematosus. Genet Mol Res. 2016;15(2):1-8. https:// doi.org/10.4238/gmr.15027626 PMid:27323066

Tsanaktsi A, Solomou EE, Liossis SN. Th1/17 cells, a subset of Th17 cells are expanded in patients with active systemic lupus erythematosus. Clin Immunol. 2018;195:101-6. https://doi. org/10.1016/j.clim.2018.08.005

Vincent FB, Northcott M, Morand EF. Clinical association of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013;15(4):R97. https://doi.org/10.1186/ar4277 PMid:23968496

Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentration in patients with systemic lupus erythematosus. Lupus. 2000;9(8):589-93. https://doi.org/10.1191/096120300678828703 PMid:11035433

Facciotti F, Larghi P, Bosotti R, Vasco C, Gagliani N, Cordiglieri C, et al. Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus. PNAS. 2020;117(13):7305-16. https://doi. org/10.1073/pnas.1917834117

Wang T, Mei Y, Li Z. Research progress on regulatory B cells in systemic lupus erythematosus. BioMed Res Int. 2019;2019:1-7. https://doi.org/10.1155/2019/7948687 PMid:31240224

Geginat J, Vasco M, Gerosa M, Tas SW, Pagani M, Grassi F, et al. IL-10 producing regulatory and helper T-cells in systemic lupus erythematosus. Semin Immunol. 2019;44:101330. https:// doi.org/10.1016/j.smim.2019.101330 PMid:31735515

Su X, Ye L, Chen X, Zhang H, Zhou Y, Ding X, et al. MiR- 199-3p promotes ERK-mediated IL-10 production by targeting poly (ADP-ribose) polymerase-1 in patients with systemic lupus erythematosus. Chem Biol Interact. 2019;306:110-6. https://doi. org/10.1016/j.cbi.2019.04.015 PMid:30991045

Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep. 2010;37(1):81-5. https://doi. org/10.1007/s11033-009-9533-3 PMid:19347604

Godsell J, Rudloff I, Kandane-Rathnayake R, Hoi A, Nold MF, Morand EF, et al. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep. 2016;6(34604):1-10. https://doi.org/10.1038/srep34604

Correa JE, Cortes MA, Uribe JA, Camacho LS. Comparison of plasma cytokine levels before and after treatment with rituximab in patients with rheumatoid arthritis and systemic lupus erythematosus-associated polyautoimmunity. Univ Med. 2018;59(3):21-36. https:// doi.org/10.11144/javeriana.umed59-3.cyto

Koenig KF, Groeschl I, Pesickova SS, Tesar V, Eisenberger U, Trendelenburg M. Serum cytokine profile in patients with active lupus nephritis. Cytokine. 2012;60(2):410-6. https://doi. org/10.1016/j.cyto.2012.07.004 PMid:22846145